SEC For	m 4 FORM	4	UNITED	STA	TES	s se	-		-		NGE C	юммі	SSION				
Section 16. Form 4 or Form 5 obligations may continue. See					d pur	Washington, D.C. 20549 IT OF CHANGES IN BENEFICIAL OWNEI I pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								Estimated average burden			235-0287
1. Name and Address of Reporting Person [*] Bhatt Padmanabh P.					<u>SI</u>		RNUS		ker or Tradin IARMAC		<u>C.</u> (Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below)				ner	
	Last) (First) (Middle) C/O SUPERNUS PHARMACEUTICALS, IN 1715 KEY WEST AVENUE				3. Date of Earliest Transaction (Month/Day/Year) 02/19/2021								Sr. VP of IP, CSO				
(Street) ROCKV	Street) ROCKVILLE MD 20850				4.1	Line) X Form								r Joint/Group Filing (Check Applicable n filed by One Reporting Person n filed by More than One Reporting			
(City)	(S	,	(Zip)	Derite		. 0.											
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D.)					action	ction 2A. Deen Executio			3. Transacti Code (Ins	4. Secur Dispose	4. Securities Acquired (A Disposed Of (D) (Instr. 3,		5. Amou Securitie Beneficia	nt of es ally Following	Form (D) or	: Direct c r Indirect E str. 4) 0	7. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code V				Amount	(A) o (D)	r Price	Transact (Instr. 3 a	tion(s)				
		-	able II - D (۹						uired, Dis s, options				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/ ^N	ate, T	Code (In				6. Date Exer Expiration D (Month/Day/	ate	e of Securities		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	S Ownersh Form: Ily Direct (D or Indirec (I) (Instr.	Ownership	Beneficial Ownership t (Instr. 4)
				c	Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Employee Stock Option (Right to Buy)	\$29.61	02/19/2021			A		17,000		(1)	02/19/2031	Common Stock	17,000	\$0	17,00	0	D	

Explanation of Responses:

1. The option vests in four equal annual installments beginning on February 19, 2022.

Remarks:

Exhibit 24 - Power of Attorney

/s/ James P. Kelly, as attorney-02/23/2021

in-fact

Date ** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Power of Attorney

Know all by these presents, that the undersigned hereby constitutes and appoints JACK KHATTAR and JAMES KELLY, and each of them individually, with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer of Supernus Pharmaceuticals, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission and any securities exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and condition as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that each such attorney-in-fact, or each such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS THEREOF, the undersigned has caused this Power of Attorney to be executed as of this 16th day of November, 2020.

/s/ Padmanabh P. Bhatt Padmanabh P. Bhatt